CILP-M
A neo-epitope fragment of cartilage intermediate layer protein 1 generated by matrix metalloproteinase activity, enabling non-invasive monitoring of cartilage degradation and disease activity in rheumatic conditions.
Key features and values
- Targets a specific neo-epitope of CILP-1 generated by matrix metalloproteinase activity.
- Provides a non-invasive measure for assessing cartilage degradation.
- Applicable in research on rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis.
- Facilitates monitoring of disease activity and therapeutic response.
- Supports evaluation of interventions aimed at modulating cartilage remodeling.
- Complements other biomarkers for a comprehensive assessment of joint health.
- Validated for use in research settings to advance understanding of cartilage pathology.
Description
The CILP-M biomarker assay quantifies a specific neo-epitope fragment of cartilage intermediate layer protein 1 (CILP-1) generated by matrix metalloproteinase activity. This non-invasive assay serves as an indicator of cartilage degradation, providing insights into disease activity in rheumatic conditions such as rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. By measuring CILP-M levels, researchers can monitor disease progression, evaluate therapeutic efficacy, and stratify patients in clinical studies targeting cartilage remodeling pathways. The assay supports a comprehensive understanding of cartilage pathology and its role in joint diseases.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
